Chief Financial Officer Aradhana Sarin reported that AstraZeneca delivered very strong commercial performance over the first nine months of 2025, with total revenue up 11% year-on-year and core EPS up 15%. Oncology led growth at +16%, biopharmaceuticals rose 8% and rare disease increased 6%. Growth from newer medicines more than offset loss of exclusivity for Brilinta, Pulmicort and Soliris. Regionally, the U.S. delivered 11% growth, emerging markets excluding China grew 21%, and management reiterated guidance for high single-digit total revenue growth and low double-digit core EPS expansion on a constant currency basis. Sarin cautioned that fourth-quarter comparisons will face headwinds from Chinese volume-based procurement, year-end hospital orders and the absence of over $800 million in 2024 collaboration milestones, with full-year results due February 10.

AstraZeneca reported 16 positive Phase 3 readouts in 2025, representing peak revenue opportunities exceeding $10 billion. Late-year achievements included FDA approvals for Imfinzi in perioperative gastric cancer and Enhertu in first-line HER2-positive breast cancer, and FDA priority review acceptance for baxdrostat in hypertension. Management expects 2026 launches of baxdrostat, camizestrant and garadacimab, all currently under regulatory review, and highlighted ongoing preparation for commercialization in key specialty and primary care channels.

R&D spending is forecast toward the upper end of the low-20% range of total revenue in 2026 to support 104 ongoing Phase 3 studies. Patient enrollment is set to accelerate, driven by large-scale cardiovascular, renal and metabolism outcome trials. AstraZeneca detailed two AI platforms: IDA for synthetic process development, which may cut scale-up timelines by up to 50%, and QCS for computational pathology to match patients to ADC treatments. The acquisition of Modela AI aims to enhance pathology foundation models and strengthen the company’s decision-making framework, which ranks projects across therapy areas without pre-allocated budgets.

Management reiterated confidence in the $80 billion revenue target for 2030, noting consensus estimates have risen from $67 billion at target announcement to current levels near the ambition. In oncology, underappreciated assets such as AZD0120 (dual CD19/BCMA CAR-T) and the PD-1/TIGIT bispecific rilvegostomig are highlighted as growth drivers alongside lifecycle management of key franchises. On U.S. policy, the phased Most Favored Nation agreement is expected to impact a low-single-digit percentage of global sales in 2026, primarily within Medicaid, with adjustments incorporated into early-year guidance.